Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
  • C07D239/72—Quinazolines; Hydrogenated quinazolines
  • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
  • C07D239/84—Nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the invention relates to compounds of the formula I.
• Ar is phenyl or naphthyl which is unsubstituted or simply substituted by R and / or R,
• R 1 , R 2 , R 3 , R 4 each independently of one another H, A, OA, Hai, CF 3 , OH, N0 2 , NH 2 , NHA, NA 2 , NH-CO-A, NH-CO-Ph, SA, SO-A, S0 2 -A, S0 2 - Ph, CN, OCF 3 , CO-A, C0 2 H, C0 2 A, CO-NH 2 , CO-NHA, CO-NA 2 , S0 2 NH 2 , S0 2 NHA, S0 2 NA 2 or unsubstituted or mono- or polysubstituted by A, OA, shark or CF 3
• a alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms having 1, 2, 3, 4, 5 or 6 carbon atoms
• R 5 , R 6 , R 7 , R 8 each independently of one another are H, A, unsubstituted or mono- or polysubstituted by A, OA, shark, CF 3 means, where R 5 and R 7 , R 5 and R 6 , R 7 and R 8 can form 5-7-membered rings,
• R 5 , R 6 , R 7 and R 8 are simultaneously H and none of the radicals R 1 , R 2 , R 3 , R 4 OH, N0 2 , NH 2 , NHA, NA 2 , NH-CO-A, NH-CO-Ph, SA, SO-A, S0 2 -A, S0 2 -Ph, CN, OCF 3 , CO-A, C0 2 H, C0 2 A, CO-NH 2 , CO-NHA, CO-NA 2 , S0 2 NH 2 , S0 2 NHA, S0 NA 2 or unsubstituted or mono- or polysubstituted by A, OA, shark or CF 3 are phenyl, excepted ,
• the invention also relates to the use of the compounds of the formula I and their salts and solvates as NHE-3 inhibitors.
• inhibitors of the subtype 3 sodium / proton exchanger are e.g. in EP 0 825 178.
• the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments.
• the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine.
• the Na + / H + exchanger is a family with at least 6 different isoforms (NHE-1 to NHE-6), all of them are cloned. While the NHE-1 subtype is ubiquitously distributed throughout the body in all tissues, the remaining NHE subtypes are selectively expressed in specific organs such as the kidney or in the lumen wall and contraluminal wall of the small intestine. This distribution reflects the specific functions that the various isoforms serve, namely on the one hand the regulation of the intracellular pH and cell volume by the subtype NHE-1 and on the other hand the Na + uptake and reuptake in the intestine and kidney by the Isoforms NHE-2 or NHE-3. The NHE-4 isoform was found mainly in the stomach. The expression of NHE-5 is limited to brain and neuronal tissue. NHE-6 represents the isoform that forms the sodium proton exchanger in the mitochondria.
• the NHE-3 isoform is particularly expressed in the apical membrane of the proximal renal tubules; an NHE-3 inhibitor therefore exercises a kidney protection effect.
• NHE-3 inhibitors inhibit or reduce tissue damage and cell necrosis following pathophysiological hypoxic and ischemic events that lead to activation of NHE activity, such as during renal ischemia or during kidney transplant removal, transport, and reperfusion during kidney transplantation ,
• the compounds of the formula I have a cytoprotective effect by preventing the excessive absorption of sodium and water into the cells of organs which are under-supplied with oxygen.
• the compounds of formula I lower blood pressure and are suitable as active pharmaceutical ingredients for the treatment of hypertension. They are also suitable as diuretics.
• the compounds of the formula I alone or in conjunction with NHE inhibitors of other subtype specificity, have anti-ischemic effects and can be used for thromboses, atherosclerosis, vascular spasms, for protecting organs, for example kidney and liver, before and during operations, and for chronic or acute kidney failure. They can also be used to treat stroke, himedema, ischemia of the nervous system, various forms of shock, e.g. allergic, cardiological, hypovolaean or bacterial shock, and to improve respiratory drive in the following conditions, for example: central sleep apneas, sudden
• the compounds of formula I have an inhibitory effect on the proliferation of cells, for example fibroblast cell proliferation and the proliferation of vascular smooth muscle cells and can therefore be used for the treatment of diseases in which cell proliferation is a primary or secondary cause.
• the compounds of formula I can be used against late diabetic complications, cancer, fibrotic diseases, endothelial dysfunction, organ hypertrophy and hyperplasia, especially in prostatic hyperplasia or prostate hypertrophy. They are also suitable as diagnostics for the determination and differentiation of certain forms of hypertension, atherosclerosis, diabetes and proliferative diseases.
• the compounds of the formula I also have an advantageous effect on the level of the serum lipoproteins, they can be used for the treatment of an increased blood lipid level alone or in combination with other medicaments.
• the invention relates to the use of compounds of the formula I as claimed in claim 1 and their physiologically acceptable salts and / or solvates for the manufacture of a medicament for the treatment of thromboses, ischemic conditions of the heart, peripheral and central nervous system and stroke, ischemic conditions of peripheral organs and limbs and for the treatment of shock conditions.
• the invention further relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable Salts and / or solvates for the manufacture of a medicament for use in surgical operations and organ transplants and for the preservation and storage of grafts for surgical measures.
• the invention also relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable salts and / or solvates for the manufacture of a medicament for the treatment of diseases in which cell proliferation is a primary or secondary cause, for the treatment or prophylaxis of disorders of
• the invention further relates to the use of compounds of the formula I according to claim 1 and their physiologically acceptable salts and / or solvates for the manufacture of a medicament for the treatment of ischemic kidney, ischemic bowel disease or for the prophylaxis of acute or chronic kidney disease.
• the compounds of formula I are also suitable for the treatment of bacterial and parasitic diseases.
• Hydrates and solvates are e.g. the hemi, mono- or dihydrates, among solvates e.g. Alcohol addition compounds such as with methanol or ethanol.
• A means alkyl, is linear or branched, and has 1, 2, 3, 4, 5 or 6 carbon atoms.
• A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2 , 2-
• OA preferably means methoxy, ethoxy, propoxy, isopropoxy or butoxy.
• Shark is preferably F, Cl or Br, but also I, in particular F, Cl or Br.
• Ph denotes an unsubstituted phenyl radical, unless stated otherwise.
• Ar preferably denotes unsubstituted phenyl or naphthyl, further preferably monosubstituted phenyl or naphthyl, for example by A, fluorine, chlorine, bromine, iodine, methoxy, ethoxy, 5 propoxy, butoxy or CF 3 .
• Ar is unsubstituted or substituted by A, fluorine, chlorine, bromine, iodine, methoxy, ethoxy, propoxy, butoxy or CF 3 phenyl monosubstituted.
• R 5 , R 6 , R 7 and R 8 are preferably H at the same time or, independently of one another, H or A, which is defined as indicated above.
• Y preferably adopts one of the following structures
• n 1, 2 or 3, preferably 1 or 2.
• Y preferably adopts one of the following structures: 5
• R 5 and R 6 have the meaning given above and n is 1, 2 or 3, preferably 1 or 2.
• Y preferably adopts one of the following structures:
• R 7 and R 8 have the meaning given above and n is 1, 2 or 3, preferably 1 or 2.
• the invention relates in particular to the compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above and the use thereof.
• Some preferred groups of compounds can be expressed by the following sub-formulas la to le, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
• R 1 denotes H, OH, OA, SA or shark, in particular H, OH, OCH 3 or CH 3 ;
• R 1 H, OH, OA, SA or shark in particular H, OH, OCH 3 or CH 3 R 2 H, shark, OH, A, NH 2 , N0 2 or CN, in particular H, Cl, OH, CH 3 or NH 2 .
• Ar is phenyl
• R 1 H, OH, OA, SA or shark in particular H, OH, OCH 3 or CH 3 R 2 H, shark, OH, A, NH 2 , N0 2 or CN, in particular H,
• R 3 is H, A, NH 2 or SA, in particular H or CH 3
• R 3 is H, A, NH 2 or SA, in particular H or CH 3
• R 4 H, shark, NH 2 , or N0 2, in particular H or NH 2
• R simultaneously denotes H, Ar phenyl and at least one of the radicals R 1 , R 2 , R 3 , R 4 has one of the following meanings: OH, N0 2 , NH 2 , NHA, NA 2 , NH-CO-A, NH-CO-Ph, SA, SO-A, S0 2 -A, S0 2 - Ph, CN, OCF 3 , CO-A, C0 2 H, C0 2 A , CO-NH 2 , CO-NHA, CO-NA 2 , S0 2 NH 2 , S0 2 NHA, S0 2 NA 2 or unsubstituted or mono- or polysubstituted by A, OA, shark, CF 3 .
• R simultaneously denotes H, Ar phenyl and at least one of the radicals R 1 , R 2 , R 3 , R 4 has one of the following meanings: OH, N0 2 , NH 2 , NHA, NA 2 , NH-CO
• R 1 , R 2 , R 3 , R 4 and Y have the meaning given above and R 1 is preferably H, OH, OA, SA, or F, in particular H, OH, OCH 3 or CH 3 .
• R 2 preferably denotes H, Cl, A, NH 2 , N0 2 , SCH 3 , SOCH 3 , S0 2 CH 3 , OCH 3 , OH, CN, CF 3 , OCF 3 or F, in particular H, Cl, F, Br , OH, CH 3 , N0 2 or NH 2 , R 2 in the formulas If to lk Cl very particularly preferably.
• R 3 preferably denotes H, Cl, A, NH 2 , N0 2 , SCH 3 , CN, C 2 H 5 , OCF 3 or
• R 3 in the formulas If to lk is very particularly preferably CH 3 .
• R 4 preferably denotes H, F, NH 2 or N0 2 , in particular H or NH 2 .
• Y has the meaning given above in the formulas If to lk. Y preferably assumes one of the following meanings:
• Y particularly preferably has one of the following meanings:
• hydrochlorides and p-toluenesulfonates of the compounds of the formulas 11 to 110 are very particularly preferred.
• the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
• the 2-guanidino-4-aryl-quinazolines of the formula I are preferably prepared by using o-aminophenyl ketones or o-aminonaphthyl ketones of the formula II
• R 1 , R 2 and Ar have the meanings given in claim 1, with 1-cyanguanidine or a correspondingly N-alkylated or N-arylated 1-cyanguanidine of the formula NC-Y, where Y has the meaning given above.
• the reaction can be carried out in an inert solvent.
• Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether,
• Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene
• chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane
• Alcohols such as methanol, ethanol, isopropanol, n-propanol
• Tetrahydrofuran (THF) or dioxane Tetrahydrofuran (THF) or dioxane
• Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of the solvents mentioned.
• DMF water or an alcohol
• the reaction is very particularly preferred without a solvent, i.e. in the melt, carried out at temperatures between 100 and 200 ° C.
• an acidic catalyst such as AICI 3 , TiCI, p-toluenesulfonic acid, BF 3 , acetic acid, sulfuric acid, oxalic acid, POCI 3 or phosphorus pentoxide is advantageous.
• a preferred variant is that one of the reactants is already in the form of a salt, e.g. is used as the hydrochloride.
• X -S-alkyl, -S-aryl, -O-alkyl or -OAryl and alkyl preferably the meaning of A and aryl given above has the meaning of Ar given above, with a compound of formula II.
• HY particularly preferably means guanidine.
• a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
• acids that provide physiologically acceptable salts are suitable for this implementation.
• So inorganic acids can be used, e.g. Sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, also organic acids, especially aliphatic, alicyclic, araiiphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
• Formic acid acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane or ethanesulfonic acid, • 2-ethanesulfonic acid, • ethanesulfonic acid, Benzenesulfonic acid, p-
• Toluenesulfonic acid naphthalene mono- and disulfonic acids, lauryl sulfuric acid. Salts with physiologically unacceptable acids, e.g. Picrates can be used for the isolation and / or purification of the compounds of the formula I.
• the invention further relates to the use of the compounds of the formula I as NHE-3 inhibitors and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and optionally in combination with one or more further active ingredients.
• the invention further relates to pharmaceutical preparations containing at least one NHE-3 inhibitor of the formula I and / or one of its physiologically acceptable salts and solvates.
• Suitable carriers are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin , Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
• Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions for parenteral use, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for which topical application ointments, creams or powders, or transdermally in patches.
• the new compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injectables.
• the stated preparations can be sterilized and / or
• Excipients such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active ingredients, e.g. one or more vitamins.
• lubricants such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active ingredients, e.g. one or more vitamins.
• Aerosols or sprays are suitable e.g. Solutions, suspensions or emulsions of the active ingredient of formula I in a pharmaceutically acceptable solvent.
• Salts and solvates can be used to treat and / or prevent the diseases or conditions described above.
• the substances according to the invention are generally preferably administered in doses between about 0.1 and 100 mg, in particular between 1 and 10 mg, per dosage unit.
• the daily Dosage is preferably between about 0.001 and 10 mg / kg body weight.
• the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of excretion and combination of drugs and severity of the respective disease to which the therapy applies. Oral application is preferred.
• Example 2 1.20 g of N- (5-methoxy-4-phenyl-quinazolin-2-yl) guanidinium chloride were stirred with 8.00 g of pyridinium chloride at 170 ° C. for 6 h. The cooled melt was then treated with 20 ml of a Na 2 S 2 0 4 solution. The precipitate obtained was isolated, dissolved in methanol and the solution acidified with HCI-containing isopropanol. After removal of the solvent, the residue was crystallized from acetonitrile, whereby N- (5-Hydroxy-4-phenyl-quinazolin-2-yl) guanidinium chloride was obtained (mp. 310 ° C).
• Example 3 A mixture of 3.01 g of 2-amino-5-chlorobenzophenone, 2.55 g of N-cyano
• N'-methylguanidine and 7.42 g of p-toluenesulfonic acid monohydrate were stirred in the melt at 150 to 160 ° C. for 2 h.
• the cooled melt was mixed with methanol and for 30 min. stirred at 65 ° C.
• the residue obtained after filtration was discarded, the filtrate was mixed with water and ethyl acetate and again for 30 min. stirred at 65 ° C.
• the mixture was then left to crystallize in an ice bath with stirring, giving N- (6-chloro-4-phenyl-quinazolin-2-yl) -N'-methyl-guanidinium-p-toluenesulfonate (mp. 268-269 ° C.).
• Example 3 worked up, whereby N- [6-chloro-4- (2-nitro-phenyl) -quinazolin-2-yl] -N'-ethyl-guanidinium-p-toluenesulfonate was obtained (mp. 298-300 ° C.) ,
• pTsOH means p-toluenesulfonic acid.
• CD CD D CD CD CD cn cn cn cn cn cn cn cn cn cn cn 4 ** * -I *** - -I ****** -t * -fc * -r ** ⁇ 4 * lake - ⁇ • * -I *** -. 00 co 00 00 00 00 CO 00 00 00 ro
• the compounds of the formula I were characterized with regard to their selectivity towards the isoforms NHE- to NHE-3.
• the three isoforms were stably expressed in mouse fibroblast cell lines.
• the inhibitory effect of the compounds was assessed by determining the EIPA-sensitive 22 Na + uptake into the cells after intracellular acidosis.
• the LAP1 cell lines expressing the isoforms NHE-1, -2 and -3 were developed by Prof. J. Pouyssegur (Nice,
• the transfections were carried out according to the method of Franchi et al. (1986).
• the cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 10% inactivated fetal calf serum (FCS).
• DMEM Dulbecco's modified Eagle medium
• FCS inactivated fetal calf serum
• the cells were first incubated for 30 minutes in a NHCl-containing bicarbonate and sodium free buffer.
• the extracellular NH CI was then removed by washing with a buffer free of bicarbonate, NH 4 CI and sodium.
• the cells were then incubated in a bicarbonate-free, NaCl-containing buffer. Only those Cells that functionally express NHE could survive in the intracellular acidification to which they were exposed.
• mice fibroblast cell lines expressing the isoforms NHE-1, NHE-2 and NHE-3 compounds according to the method described by Counillon et al. (1993) and Scholz et al. (1995) described procedure for selectivity compared to the isoforms.
• the cells were acidified intracellularly using the NH CI prepulse method and then by incubation in a bicarbonate-free 22 Na + -containing buffer. Due to the intracellular acidification, NHE was activated and sodium was absorbed into the cells. The effect of the test compound was expressed as an inhibition of the 22 Na + uptake sensitive to EIPA (ethyl isopropylamiloride).
• EIPA ethyl isopropylamiloride
• the cells expressing NHE-1, NHE-2 and NHE-3 were seeded at a density of 5-7.5 x 10 4 cells / well in microtiter plates with 24 wells and grown to confluence for 24 to 48 hours.
• the medium was aspirated and the cells were incubated for 60 minutes at 37 ° C. in the NH 4 CI buffer (50 mM NH 4 CI, 70 mM choline chloride, 15 mM MOPS, pH 7.0).
• the buffer was then removed and the cells were quickly overlaid twice with the choline chloride washing buffer (120 mM choline chloride, 15 mM PIPES / Tris, 0.1 mM ouabain, 1 mM MgCl 2 , 2 mM CaCl 2 , pH 7.4)
• the cells were then aspirated with the choline chloride loading buffer (120 mM choline chloride, 15 mM PIPES / Tris, 0.1 mM PIPES / Tris, 0.1 mM Quabain, 1mM MgCl 2 , 2mM CaCl 2 , pH 7.4, 22 Overlaid Na * (0.925 kBg / 100 ml loading buffer)) and incubated therein for 6 minutes. After the incubation period had elapsed, the incubation buffer was aspirated.
• the incubation buffer was aspirated.
• the cells were quickly washed four times with ice-cold phosphate-buffered saline (PBS). The cells were then solubilized by adding 0.3 ml of 0.1 N NaOH per well. The cell fragment-containing solutions were transferred to scintillation tubes. Each well was washed twice more with 0.3 ml of 0.1 N NaOH and the washing solutions were also placed in the appropriate scintillation tubes. Scintillation cocktail was added to the tubes containing the cell lysate and the radioactivity absorbed into the cells was determined by determining the ⁇ radiation.
• PBS ice-cold phosphate-buffered saline
• Example A Injection glasses
• a solution of 100 g of an NHE-3 inhibitor of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized and sterile sealed under sterile conditions , Each injection jar contains 5 mg of active ingredient.
• a mixture of 20 g of an NHE-3 inhibitor of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
• a solution of 1 g is prepared of an NHE-3 inhibitor of the formula I, 9.38 g of NaH 2 P0 4 ⁇ 2 H 2 0, 28.48 g Na 2 HP0 4 • 12 H 2 0 and 0.1 g of
• Benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
• Example D ointment
• Example F coated tablets
• Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
• Example G capsules
• a solution of 1 kg of NHE-3 inhibitor of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7655015

Family Applications (1)

Country Status (16)

Families Citing this family (16)

Family Cites Families (5)

• 2000
  • 2000-09-05 DE DE10043667A patent/DE10043667A1/de not_active Withdrawn
• 2001
  • 2001-08-13 JP JP2002525118A patent/JP2004508360A/ja active Pending
  • 2001-08-13 WO PCT/EP2001/009325 patent/WO2002020496A1/de not_active Application Discontinuation
  • 2001-08-13 CA CA002421222A patent/CA2421222A1/en not_active Abandoned
  • 2001-08-13 CN CN01815093A patent/CN1450996A/zh active Pending
  • 2001-08-13 AU AU2001285886A patent/AU2001285886A1/en not_active Abandoned
  • 2001-08-13 BR BR0113583-0A patent/BR0113583A/pt not_active Application Discontinuation
  • 2001-08-13 US US10/363,169 patent/US20040039001A1/en not_active Abandoned
  • 2001-08-13 EP EP01965191A patent/EP1315704A1/de not_active Withdrawn
  • 2001-08-13 MX MXPA03001877A patent/MXPA03001877A/es unknown
  • 2001-08-13 CZ CZ2003858A patent/CZ2003858A3/cs unknown
  • 2001-08-13 RU RU2003108861/04A patent/RU2003108861A/ru not_active Application Discontinuation
  • 2001-08-13 KR KR10-2003-7002570A patent/KR20030062404A/ko not_active Application Discontinuation
  • 2001-08-13 PL PL36039101A patent/PL360391A1/xx unknown
• 2003
  • 2003-03-04 NO NO20030999A patent/NO20030999D0/no not_active Application Discontinuation
  • 2003-04-03 ZA ZA200302633A patent/ZA200302633B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events